What is claimed is:
1. A method of reducing proliferation of or extracellular matrix production by a cell in a mammal comprising administering to the mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle, wherein the zvegf4 antagonist is selected from the group consisting of:
anti-zvegf4 antibodies;
inhibitory polynucleotides;
inhibitors of zvegf4 activation; and
mitogenically inactive, receptor-binding variants of zvegf4.
2. The method of claim 1 wherein proliferation of mesangial, epithelial, endothelial, smooth muscle, fibroblast, osteoblast, osteoclast, neuronal, stromal, stellate, or interstitial cells is reduced.
3. The method of claim 1 wherein proliferation of tumor cells is reduced.
4. The method of claim 3 wherein the tumor cells are prostate tumor cells.
5. The method of claim 1 wherein extracellular matrix production is reduced.
6. The method of claim 1 wherein the mammal is suffering from a fibroproliferative disorder of kidney.
7. The method of claim 1 wherein the mammal is suffering from a fibroproliferative disorder of liver.
8. The method of claim 1 wherein the mammal is suffering from a fibroproliferative disorder of bone.
9. The method of claim 1 wherein the zvegf4 antagonist is selected from the group consisting of anti-zvegf4 antibodies and inhibitory polynucleotides.
10. The method of claim 9 wherein the antagonist is an anti-zvegf4 antibody.
11. The method of claim 10 wherein the antibody is a monoclonal antibody.
12. The method of claim 9 wherein the antagonist is an inhibitory polynucleotide selected from the group consisting of antisense polynucleotides, ribozyme-encoding polynucleotides, and external guide sequence-encoding polynucleotides.
13. The method of claim 1 wherein the zvegf4 antagonist is administered in combination with an antagonist of a second growth factor.
14. The method of claim 11 wherein the second growth factor is EGF, a TGF-, or an FGF.
15. A method of reducing proliferation of or extracellular matrix production by a cell in a mammal, wherein the cell is an epithelial, endothelial, smooth muscle, fibroblast, osteoblast, neuronal, or stellate cell, the method comprising administering to the mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle, wherein the zvegf4 antagonist is selected from the group consisting of:
anti-zvegf4 antibodies;
inhibitory polynucleotides;
inhibitors of zvegf4 activation; and
mitogenically inactive, receptor-binding variants of zvegf4.
16. A method of reducing proliferation of or extracellular matrix production by prostate tumor cells in a mammal, the method comprising administering to the mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle, wherein the zvegf4 antagonist is selected from the group consisting of:
anti-zvegf4 antibodies;
inhibitory polynucleotides;
inhibitors of zvegf4 activation; and
mitogenically inactive, receptor-binding variants of zvegf4.
17. A method of reducing metastasis of prostate cancer cells to bone in a mammal, the method comprising administering to the mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle, wherein the zvegf4 antagonist is selected from the group consisting of:
anti-zvegf4 antibodies;
inhibitory polynucleotides;
inhibitors of zvegf4 activation; and
mitogenically inactive, receptor-binding variants of zvegf4.
18. A method of treating a fibroproliferative disorder in a mammal comprising administering to the mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle, wherein the zvegf4 antagonist is selected from the group consisting of anti-zvegf4 antibodies, inhibitors of zvegf4 activation, mitogenically inactive receptor-binding zvegf4 variant polypeptides, and inhibitory polynucleotides.
19. The method of claim 18 wherein the fibroproliferative disorder is a fibroproliferative disorder of liver.
20. The method of claim 18 wherein the fibroproliferative disorder is a fibroproliferative disorder of kidney.
21. The method of claim 18 wherein the fibroproliferative disorder is a fibroproliferative disorder of bone.
22. The method of claim 18 wherein the antagonist is an anti-zvegf4 antibody.
23. The method of claim 22 wherein the antibody is a monoclonal antibody.
24. A method of reducing stellate cell activation in a mammal comprising administering to the mammal a composition comprising a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle, wherein the zvegf4 antagonist is selected from the group consisting of anti-zvegf4 antibodies, mitogenically inactive receptor-binding zvegf4 variant polypeptides, and inhibitory polynucleotides, in an amount sufficient to reduce stellate cell activation.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of pouring a fluid from a container having a spout with a fluid outlet, the method comprising:
tilting the container to at least one angle that causes fluid to enter the spout, tilting causing the fluid to exit the spout through the fluid outlet, the fluid passing through the spout causing the mechanical member to move; and
correlating movement of the mechanical member with visual indicia showing the volume of fluid passing through the fluid outlet.
2. The method as defined by claim 1 wherein the mechanical member is within the spout.
3. The method as defined by claim 1 wherein the mechanical member moves along a track.
4. The method as defined by claim 3 wherein the mechanical member includes a rotatable member that moves along the track.
5. The method as defined by claim 1 further including a drip cup.
6. A spout comprising:
a housing forming an inlet, an outlet, and a channel between the inlet and the outlet, the housing having a housing volume between the inlet and the outlet; and
indicia adapted to show the approximate volume of fluid that passes through the outlet in real time, the indicia including indicia identifying at least one volume that is greater than the housing volume between the inlet and the outlet.
7. The spout as defined by claim 6 wherein the indicia includes movement of a mechanical member.
8. The spout as defined by claim 6 wherein the indicia include graduations formed on the housing.
9. The spout as defined by claim 6 wherein the housing includes a pour chamber having a pour inlet and a pour outlet, the housing also including an indicating chamber having an indicating inlet for receiving fluid, the indicating chamber including the indicia.
10. The spout as defined by claim 6 wherein the indicia includes an audible sound.
11. The spout as defined by claim 10 further including a sensor adapted to produce the audible sound as a function of fluid flowing through the housing.
12. The spout as defined by claim 6 wherein the housing includes an indicating chamber in fluid communication with the channel, the indicating chamber having the indicia and receiving an amount of fluid generally proportional to fluid passing through the outlet.
13. A spout comprising:
a housing forming an inlet, an outlet, and a channel between the inlet and the outlet, the housing having a housing volume between the inlet and the outlet; and
means for showing the approximate volume of fluid that passes through the outlet in real time, the showing means including means for identifying at least one volume that is greater than the housing volume between the inlet and the outlet.
14. The spout as defined by claim 13 wherein the showing means includes indicia.
15. The spout as defined by claim 13 wherein the showing means includes movement of a mechanical member.
16. The spout as defined by claim 13 wherein the showing means includes graduations formed on the housing.
17. The spout as defined by claim 13 wherein the showing means includes an audible sound.
18. The spout as defined by claim 13 wherein the housing includes means for receiving an amount of fluid that is generally proportional to the fluid flowing through the outlet.
19. The spout as defined by claim 18 wherein the receiving means includes an indicating chamber in fluid communication with the channel.
20. A method of dispensing fluid from a container, the method comprising:
providing a dispenser having a chamber with a fluid inlet and a fluid outlet, the fluid inlet being larger than the fluid outlet, the chamber having indicia for identifying fluid levels within the chamber when fluid exits the fluid outlet during a single pour;
permitting fluid to begin filling the chamber; and
correlating the level of the fluid with the indicia to identify the volume of fluid passing through the fluid outlet.